Abstract
ObjectiveTo delineate, within the framework of current clinical practice and criteria, the sustainability of first-line immuno-suppressive treatment discontinuation in rheumatoid arthritis (RA) and the impact of residual disease in remission...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have